ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2009
A novel bioassay model to determine clinically significant bisphosphonate levels.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- A Systematic Review of the Effects of Bisphosphonates on Osteoblasts In Vitro.Calcified tissue international · 2025Pooled it
- Hesperetin modulates osteoprogenitor cells and macrophages under zoledronic acid and inflammatory stress.Archives of oral biology · 2026Article
- Micro/nano-structured titanium surfaces promote endothelial responses and angiogenic activity under zoledronic acid exposure.BMC oral health · 2026Article
- Calcium Phosphate Bone Substitutes in the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Review.Journal of functional biomaterials · 2026Review
- Article
- The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.Nature communications · 2024Article
- Review
- A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.Medicina (Kaunas, Lithuania) · 2023Article
- Zoledronic acid affects the process ofFrontiers in cellular and infection microbiology · 2023Article
- Gingival cell growth with antiresorptive treatment combined with corticosteroids or antiestrogen.Clinical and experimental dental research · 2021Article
- Functional Analyses of FourInternational journal of molecular sciences · 2021Article
- Inhibitory Effects of Alendronate on Adhesion and Viability of Preosteoblast Cells on Titanium Discs.European journal of dentistry · 2021Article
- Geranylgeraniol prevents zoledronic acid-mediated reduction of viable mesenchymal stem cells via induction of Rho-dependent YAP activation.Royal Society open science · 2021Article
- Alendronate and omeprazole in combination reduce angiogenic and growth signals from osteoblasts.Bone reports · 2021Article
- A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw.Frontiers in oral health · 2021Review
- Synthetic Hydroxyapatite Inhibits Bisphosphonate Toxicity to the Oral Mucosa In Vitro.Materials (Basel, Switzerland) · 2020Article
- Calcium Phosphate Ceramics Can Prevent Bisphosphonate-Related Osteonecrosis of the Jaw.Materials (Basel, Switzerland) · 2020Article
- Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy.Scientific reports · 2019Article
- Minimally effective concentration of zoledronic acid to suppress osteoclastsExperimental and therapeutic medicine · 2018Article
- Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces.Clinical oral investigations · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
purposeBisphosphonate-associated osteonecrosis (BON) is a recently recognized oral complication of bisphosphonate (BP) therapy. Currently, research into the pathogenesis of BON has been hampered by being deficient in studies capable of measuring the level of BP in saliva or at the bone-soft tissue interface. The objective of this current study was to develop a novel bioassay model representative of the oral levels of BPs in patients presenting with or at risk for BON.
methodsZoledronic acid (ZA) injectable was used to develop standardized MTS cell proliferation assay curves at concentrations of 0-10 microM, which were used either in a dilution in normal media, mimicking BP freed from bone or used to "spike" saliva individuals not taking BPs and mimicking BP levels being excreted. This bioassay was then used to estimate BP levels from samples of saliva and bone ex vivo from patients with and without BON.
resultsSaliva and bone from patients with existing BON showed levels of BP ranging from 0.4 to 4.6 microM, while patients receiving IV infusion of BP and naïve to BON showed levels in saliva ranging from 0.4 to 5 microM. All control specimens and patients naïve to BP showed levels at 0 microM.
conclusionsGiven the fact that BPs are poor candidates for detection using standard methods (HPLC), this bioassay provides us with the ability to estimate clinically relevant concentrations of BP capable of producing apoptosis and the inhibition cell proliferation of oral mucosal cells based on previous studies. Subsequently, apoptosis and the inhibition of proliferation could lead to BON, secondary to the exposure of the bone in the unique microenvironment of the oral cavity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.